摘要
目的:估算131I首次"清甲"中,分化型甲状腺癌(DTC)患者腮腺、颌下腺内照射吸收剂量。方法:前瞻性纳入术后拟行131I治疗的DTC患者40例,其中女33例,男7例,年龄(44±15)岁。患者在服用131I3.7GBq后1、2、3、4、12、24、48h行头颈部前、后位静态显像,分别在前、后位图像中勾画腮腺、颌下腺感兴趣区(ROI),以大脑实质作为本底行本底校正。将不同时间点腮腺、颌下腺的放射性计数转变为放射性活度值,利用Origin7.0软件绘制唾液腺时间-放射性活度曲线并计算曲线下面积。依照美国核医学会医用内照射剂量学委员会提出的内照射吸收剂量学计算方法,计算唾液腺的吸收剂量。结果:腮腺、颌下腺平均吸收剂量分别为(0.15±0.10)mGy/MBq、(0.19±0.07)mGy/MBq。结论:131I首次"清甲"中,DTC患者唾液腺辐射吸收剂量较低。
Objective： To estimate the individual absorbed dose to the parotid and submandibular glands in patients with differentiated thyroid carcinoma （DTC） receiving ^131I ablative therapy. Methods： Forty patients, including 7 male, 33 female, aged from 17-63（44±15）years, with DTC after thyroidectomy were prospectively recruited in this study. Head-neck anterior and posterior static scintigrams were obtained at 1, 2, 3, 4, 12, 24, 48h after administration of 3.7GBq radioiodine. Manually drawn regions of interest of the parotid and submandibular glands were used to determine the activities arising from salivary glands after background correction. The cumulative activites of salivary glands were computed via area under time-activity curves by Origin 7.0 software. According to MIRD methods, absorbed dose of salivary glands was calculated. Results： The mean absorbed dose to parotid and submandibular gland was （0.15±0.10）mGy/MBq, （0.19＋0.07）mGy/MBq, respectively. Conclusion： Radiation dose to the salivary glands of DTC patients receiving ^131I abahive therapy is low.
出处
《中国临床医学影像杂志》
CAS
北大核心
2009年第8期595-598,共4页
Journal of China Clinic Medical Imaging
